

Claims

1. An anti-FXII antibody comprising
 - (i) a V_H comprising a CDRH1 comprising a sequence set forth in SEQ ID NO:1; a
5 CDRH2 comprising a sequence set forth in SEQ ID NO:2; and a CDRH3 comprising a sequence set forth in SEQ ID NO:3; and
 - (ii) a V_L comprising a CDRL1 comprising a sequence set forth in SEQ ID NO:4; a
CDRL2 comprising a sequence set forth in SEQ ID NO:5; and a CDRL3 comprising
a sequence set forth in SEQ ID NO:6;
- 10 for use in a method of treating or preventing hereditary angioedema (HAE) in a subject, wherein the antibody is administered subcutaneously to the subject.
2. The anti-FXII antibody for use according to claim 1, wherein the anti-FXII antibody comprises a V_H comprising a sequence set forth in SEQ ID NO: 7 and a V_L comprising
15 a sequence set forth in SEQ ID NO:8.
3. The anti-FXII antibody for use according to any of claims 1 or 2, wherein the anti-FXII antibody is an IgG, preferably an IgG4 antibody.
- 20 4. The anti-FXII antibody for use according to claim 3, wherein the antibody comprises a mutation to proline at position 228 of the hinge region according to the EU numbering system.
5. The anti-FXII antibody for use according to any of claims 1 to 4, wherein the anti-FXII
25 antibody comprises a heavy chain sequence set forth in SEQ ID NO:9 and a light chain sequence set forth in SEQ ID NO:10.
6. The anti-FXII antibody for use according to claim 5, wherein the heavy chain comprises an additional lysine linked to the last amino acid of SEQ ID NO:9.
- 30 7. The anti-FXII antibody for use according to any of claims 1 to 6, wherein the anti-FXII antibody is administered in an amount to maintain a concentration of the antibody of at least 5 µg/ml between two subsequent administrations of the antibody.

8. The anti-FXII antibody for use according to any of claims 1 to 7, wherein the antibody is administered at a dosage of 70 mg to 700 mg once every 1-3 months, preferably once every 1-2 months.
- 5 9. The anti-FXII antibody for use according to any of claims 1 to 8, wherein the antibody is administered at a dosage of 150 mg to 250 mg, preferably 170 mg to 220 mg, more preferably 200 mg.
- 10 10. The anti-FXII antibody for use according to any of claims 1 to 8, wherein the antibody is administered at a dosage of 50 mg to 150 mg, preferably 70 mg to 130 mg, more preferably 100 mg.
- 15 11. The anti-FXII antibody for use according to any of claims 1 to 10, wherein the antibody is administered every 1-2 months, preferably once every 1 month.
- 20 12. The anti-FXII antibody for use according to any of claims 1 to 11, wherein the subject is a human patient having, suspected of having or at risk for HAE.
- 25 13. The anti-FXII antibody for use according to any of claims 1 to 12, wherein the method includes an administration of a loading dose of the anti-FXII antibody.
- 30 14. The anti-FXII antibody for use according to claim 13, wherein the administration of a loading dose is an intravenous administration of the anti-FXII antibody at a dosage of between 30 mg and 400 mg, preferably between 100 and 300 mg, more preferably 200 mg.
15. The anti-FXII antibody for use according to claim 13, wherein the administration of a loading dose is a subcutaneous administration of the anti-FXII antibody at a dosage of between 70 mg and 700 mg, preferably between 200 and 500 mg, more preferably 400 mg.

16. The anti-FXII antibody for use according to any of claims 1 to 13 and 15, wherein the anti-FXII antibody is only administered subcutaneously to the subject.
- 5 17. The anti-FXII antibody for use according to any of claims 1 to 16, wherein the administration of the anti-FXII antibody reduces the risk of an HAE attack, preferably by more than 85 %, more preferably more than 90 % and even more preferably by more than 95 % or more than 98 %.
- 10 18. The anti-FXII antibody for use according to any of claims 1 to 17, wherein the anti-FXII antibody is administered in an amount sufficient to inhibit less than 60%, 50%, 40%, or 30% of the FXII-mediated kallikrein activity between two subsequent administrations of the antibody.